▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1429 by analyst upside · 2026-08-13
CYTK
Cytokinetics, Incorporated
Healthcare · Market Cap $11B · P/E 0x
ANALYST PRICE TARGET
+43.9%
implied upside to consensus target
Current Price $75.64
Consensus Target $108.85
Bull Target $146.0
Bear Target $85.0
Analysts Covering 20
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
12
Hold
2
Sell
0
52-Week Low $34.6
52-Week High $88.31
YTD Return +22.5%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-7.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $68M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $34.6
52-Week High $88.31
Current Price $75.64
Bear Target $85.0
Bull Target $146.0
● Now $75.64 ● Target $108.85
TRADING DATA
Avg Volume 2.1M
YTD Return +22.5%
Analyst Count 20
Consensus Buy
Upside to Target +43.9%
Last Updated 2026-08-13

ANALYST SUMMARY

Cytokinetics, Incorporated (CYTK) is currently trading at $75.64 with a Wall Street consensus price target of $108.85, implying potential upside of 43.9% over the next 12 months. 20 analysts currently cover CYTK, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $146.0, while the most cautious has a target of $85.0.

CYTK operates in the Healthcare sector with a market capitalisation of $11B. The stock is up 22.5% year-to-date and is currently trading near the upper end of its 52-week range of $34.6 – $88.31.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

UHS +12.5%
Universal Health Services, Inc.
$10B · P/E 7.0x · Hold
DVA +20.3%
DaVita Inc.
$12B · P/E 15.4x · Hold
GMED +20.5%
Globus Medical, Inc.
$12B · P/E 21.9x · Buy
FMS +8.3%
Fresenius Medical Care AG
$13B · P/E 12.4x · Hold
EHC +18.7%
Encompass Health Corporation
$12B · P/E 20.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CYTK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Needham reit
Buy → Buy 2026-06-17 20% win rate (5 calls)
Citigroup ● Initiated
Buy 2026-05-19 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-05-12 43% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-11 31% win rate (48 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-07 Building track record
Stifel - Reiterated
Buy → Buy 2026-05-06 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-06 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
23/30
Consensus clarity
14/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →